TEST AND PRICE LIST FOR NEXT GENERATION SEQUENCING

Next-generation sequencing can replace Sanger sequencing in clinical diagnostics.

Next-generation sequencing can replace Sanger sequencing in clinical diagnostics. Birgit Sikkema-Raddatz Department of Genetics, University Medical Center Groningen The Netherlands Groningen GRONINGEN

La diagnostica molecolare nelle neoplasie colo-rettali. A do Scarpa. U iversita di Vero a

La diagnostica molecolare nelle neoplasie colo-rettali C-NET A do Scarpa e Dipartime to Pato ogia e U iversita di Vero a La stessa malattia puo avere diverse patogenesi cucchiaio moneta forchetta Gastrointestinal

patient guide CancerNext TM - A Genetic Test for Hereditary Cancer

patient guide CancerNext TM - A Genetic Test for Hereditary Cancer What is hereditary cancer? Cancer affects many people in the U.S. more than 1.6 million people are estimated to be diagnosed with cancer

Nuovi Scenari in Oncologia. G. Zoppoli X-Files in Nutrizione Clinica e Artificiale, 08/06/2012

Nuovi Scenari in Oncologia G. Zoppoli X-Files in Nutrizione Clinica e Artificiale, 08/06/2012 WHAT is cancer? «Cancer is a genetic disease of the somatic cell» [B. Vogelstein] Ten years ago Now [Cell.

Corporate Medical Policy

Corporate Medical Policy Genetic Cancer Susceptibility Panels Using Next Generation Sequencing File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_cancer_susceptibility_panels_using_next_generation_sequencing

HEREDITARY CANCER GENE PANEL DG 2.3.x

HEREDITARY CANCER GENE PANEL DG 2.3.x Gene Median % covered % covered Associated Phenotype description and OMIM ID coverage >10x >20x ALK 99,5 100% 98% {Neuroblastoma, susceptibility to, 3}, 613014 APC

BRCAplus: A Genetic Test for Hereditary Breast Cancer

BRCAplus: A Genetic Test for Hereditary Breast Cancer Developed in collaboration with Fox Chase Cancer Center and the Arcadia University Genetic Counseling Program. Causes of Hereditary Breast Cancer Familial,

A Patient s Guide to Hereditary Cancer. Is Hereditary Cancer Testing Right for You?

A Patient s Guide to Hereditary Cancer Is Hereditary Cancer Testing Right for You? What is Hereditary Cancer? Most cancers occur in people who do not have a strong family history of that cancer. This is

CancerTREATMENT NGS+ NSCLC Summary Report Page 1 of 7 PATIENT SPECIMEN PHYSICIAN

Page 1 of 7 POSITIVE TEST RESULTS Biomarker Result DETECTED NEGATIVE TEST RESULTS FDA Approved Therapies Targeting Molecular Pathway TEST DESCRIPTION: CancerTREATMENT NGS+ uses Next Generation Sequencing

Launching a Cancer Genetic Laboratory to Enhance Diagnosis and Treatment

Launching a Cancer Genetic Laboratory to Enhance Diagnosis and Treatment Arthur L. Beaudet, M.D. Department of Molecular and Human Genetics Baylor College of Medicine ORIGIN AND PRECEDENT Decades of experience

Médecine de précision médecine personnalisée en Oncologie. Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN

Médecine de précision médecine personnalisée en Oncologie Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN Successful targeted drug development Rapid identification

1199 SEIU Benefit Funds Laboratory Management Program PRIOR AUTHORIZATION CODE LIST FOR OUTPATIENT MOLECULAR AND GENOMIC LABORATORY TESTS

1199 SEIU Benefit Funds Laboratory Management Program PRIOR AUTHORIZATION CODE LIST FOR OUTPATIENT MOLECULAR AND GENOMIC LABORATORY TESTS Effective January 1, 2016 Administered by evicore healthcare Refer

Test Information Sheet

Test Information Sheet GeneDx 207 Perry Parkway Gaithersburg, MD 20877 Phone: 888-729-1206 Fax: 301-710-6594 E-mail: wecare@genedx.com www.genedx.com/oncology OncoGene Dx: High/Moderate Risk Panel Sequence

Section: Genetic Testing Last Reviewed Date: October 2015. Policy No: 73 Effective Date: November 1, 2015

Medical Policy Manual Topic: Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Date of Origin: July 2014 Section: Genetic Testing Last Reviewed Date: October 2015 Policy No: 73 Effective

Hereditary Breast Cancer Panels. High Risk Hereditary Breast Cancer Panel Hereditary Breast/Ovarian/Endometrial Cancer Panel

P A T I E N T G U I D E Hereditary Breast Cancer Panels High Risk Hereditary Breast Cancer Panel Hereditary Breast/Ovarian/Endometrial Cancer Panel B a y l o r M i r a c a G e n e t i c s L a b o r a t

NEIGE. diagnosis In oncogenetics. Nicolas Sévenet 02 juillet 2012. n.sevenet@bordeaux.unicancer.fr

NEIGE g for molecular NExt g generation sequencing diagnosis In oncogenetics Nicolas Sévenet 02 juillet 2012 n.sevenet@bordeaux.unicancer.fr t@b d i f Reports 15 years Next generation sequencing 06/2011

Oncomine Cancer Panel Patient Test Report

Oncomine Cancer Panel Patient Test Report SUBJECT NFORMATON Pre-Screening Subject No.: Life Technologies Clinical Services Lab 910 Riverside Parkway, Suite 60 West Sacramento, CA 95605 Ph: (888) 734-8588

PREDICT. Comprehensive Hereditary Cancer Risk Assessment

PREDICT Comprehensive Hereditary Cancer Risk Assessment 1451 NORTHSIDE DRIVE NW SUITE A ATLANTA, GA 30318 (tel) 404.228.5027 (fax) 404.343.0087 LABSOLUTIONS.COM LABSOLUTIONS is pleased to offer its clients

Beyond BRCA the Future is Now

Beyond BRCA the Future is Now Richard P. Frieder, MD Medical Director, Intelegene Assistant Clinical Professor Department of Obstetrics and Gynecology David Geffen School of Medicine, UCLA University of

Big Data Part I: Data-Driven Life Sciences Innovation, Personalized Medicine and Research

Big Data Part I: Data-Driven Life Sciences Innovation, Personalized Medicine and Research December 9, 2014 www.mwe.com Boston Brussels Chicago Düsseldorf Frankfurt Houston London Los Angeles Miami Milan

Test Information Sheet

Test Information Sheet GeneDx 207 Perry Parkway Gaithersburg, MD 20877 Phone: 888-729-1206 Fax: 301-710-6594 E-mail: wecare@genedx.com www.genedx.com/oncology OncoGene Dx: Breast/Ovarian Cancer Panel Sequence

Gene Panels: The Next Step in Hereditary Cancer Evaluation

Gene Panels: The Net Step in Hereditary Cancer Evaluation Faculty Julia Smith, MD, PhD (Moderator) Clinical Director Cancer Screening Program at the Laura and Isaac Perlmutter Cancer Center at NYU Medical

A Decision Support Tool to Facilitate Cancer Risk Assessment and Referral for Genetics Services. Kristen Vogel Postula, MS, CGC & Leigh Baumgart, PhD

A Decision Support Tool to Facilitate Cancer Risk Assessment and Referral for Genetics Services Kristen Vogel Postula, MS, CGC & Leigh Baumgart, PhD Importance of Family History Increasing awareness of

Test Information Sheet

Test Information Sheet GeneDx 207 Perry Parkway Gaithersburg, MD 20877 Phone: 888-729-1206 Fax: 301-710-6594 E-mail: wecare@genedx.com www.genedx.com/oncology OncoGene Dx: Breast/Ovarian Cancer Panel Sequence

Ion AmpliSeq Technology

Ion AmpliSeq Technology Dr. Franziska Freund Sr. Sequencing Sales Specialist 26.06.2015 1 The world leader in serving science Ion AmpliSeq Technology: As Simple As PCR Your targets, your genome, your panel

Ovarian Cancer Genetic Testing: Why, When, How?

Ovarian Cancer Genetic Testing: Why, When, How? Jeffrey Dungan, MD Associate Professor Division of Clinical Genetics Department of Obstetrics & Gynecology Northwestern University Feinberg School of Medicine

Cancer Genomics & Precision Medicine in the 21 st Century. Lee J. Helman, MD Scientific Director for Clinical Research CCR, NCI

Cancer Genomics & Precision Medicine in the 21 st Century Lee J. Helman, MD Scientific Director for Clinical Research CCR, NCI Outline Define terms Describe vision for how genetic characterization of tumors

Microsatellite Instability (MSI) A New Paradigm in Cancer Treatment. Lynch Syndrome OUTLINE. GI Molecular Pathology

OUTLINE GI Molecular Pathology Microsatellite Instability and Lynch Syndrome GI Cancer Genotyping KRAS Mutations in Colorectal Cancer A. John Iafrate MD-PhD Department of Pathology Massachusetts General

Opportunities and Challenges in Translating Novel Discoveries into Useful Clinical Tests

Opportunities and Challenges in Translating Novel Discoveries into Useful Clinical Tests James H. Doroshow, M.D. NCI Deputy Director for Clinical and Translational Research NCI Workshop: Evidence Needed

BRCA1/2 and Lynch Syndrome Analyses with CancerNext. POSITIVE: Pathogenic Mutation Detected

SAMPLE REPORT Ordered By Contact ID:405956 Org ID:249 Physician: Sample Doctor, A Ph:111-222-3333 Client: Sample Organization (00403) Organization Address City CA 99999 US Fx:444-555-6666 Patient Name:

TABLE OF CONTENTS. Genoptix Medical Laboratory 2110 Rutherford Road Carlsbad, CA Phone: Fax:

TESTING DIRECTORY TABLE OF CONTENTS Genoptix Medical Laboratory 2110 Rutherford Road Carlsbad, CA 92008 Phone: 760.268.6200 Fax: 760.268.6201 Client Services Phone: 800.755.1605 Fax: 888.755.1604 CLIA

Approaches to Integrating Next Generation Sequencing into the Electronic Health Record

AMIA Webinar April 16, 2014 Approaches to Integrating Next Generation Sequencing into the Electronic Health Record Peter Tarczy-Hornoch, University of Washington On behalf of the Clinical Sequencing Exploratory

J Clin Oncol 32:2001-2009. 2014 by American Society of Clinical Oncology INTRODUCTION

VOLUME 32 NUMBER 19 JULY 1 2014 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment Allison W. Kurian,

High-Throughput Mutation Profiling Identifies Frequent Somatic Mutations in Advanced Gastric Adenocarcinoma

High-Throughput Mutation Profiling Identifies Frequent Somatic Mutations in Advanced Gastric Adenocarcinoma The Harvard community has made this article openly available. Please share how this access benefits

Hereditary Breast Cancer Testing. Diagnostic

Hereditary Cancer Testing Diagnostic New solutions for hereditary breast cancer. Identifying and understanding the genetic contribution to breast cancer allows for individualized disease management and

2014 CPT Code Updates

2014 CPT Code Updates This publication is a summary of The American Medical Association Current Procedural Terminology (CPT) codes published in ARUP's Laboratory Test Directory effective January 1, 2014.

Prevalenza delle mutazioni TMEM127 nel feocromocitoma sporadico

Prevalenza delle mutazioni TMEM127 nel feocromocitoma sporadico Giuseppe Opocher Veneto Institute of Oncology and Department of Medical and Surgical Sciences, University of Padova, Italy Sympathetic paraganglia

Genetics and Breast Cancer. Elly Lynch, Senior Genetic Counsellor Manager, Austin Health Clinical Genetics Service

Genetics and Breast Cancer Elly Lynch, Senior Genetic Counsellor Manager, Austin Health Clinical Genetics Service Overview Background/Our Team What is the difference between sporadic/familial cancer? How

MEDICAL POLICY STATEMENT

MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 02/24/2015 02/24/2016 04/21/2015 Policy Name Policy Number Genetic Testing, Genetic Screening and Genetic

Target enrichment using selector probes. Department of Genetics and Pathology, Uppsala University

Target enrichment using selector probes Mats Nilsson Department of Genetics and Pathology, Uppsala University Target enrichment using selector probes Even with radically improved sequencing throughput,

Umeå University. Access to the published version may require subscription.

Umeå University This is an accepted version of a paper published in Acta Oncologica. This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

The Genetics of Early- Onset Breast Cancer. Cecelia Bellcross, Ph.D., M.S.,C.G.C. Department of Human Genetics Emory University School of Medicine

The Genetics of Early- Onset Breast Cancer Cecelia Bellcross, Ph.D., M.S.,C.G.C. Department of Human Genetics Emory University School of Medicine All cancers are genetic BUT Not all cancers are hereditary

Germline testing for hereditary Cancer Syndromes. Update 2015

Germline testing for hereditary Cancer Syndromes Update 2015 Topics to be discussed Case Presentation Standard Indications for testing common syndromes Next Generation Sequencing and panel testing Unique

PATOLOGIA MOLECULAR DEL CANCER GINECOLOGICO. Xavier Matias-Guiu Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA.

PATOLOGIA MOLECULAR DEL CANCER GINECOLOGICO Xavier Matias-Guiu Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA. Carcinoma de Endometrio Cáncer de Ovario Endometrial carcinoma

Frequency of Mutations in Individuals With Breast Cancer Referred for BRCA1 and BRCA2 Testing Using Next-Generation Sequencing With a 25-Gene Panel

Frequency of Mutations in Individuals With Breast Cancer Referred for BRCA1 and BRCA2 Testing Using Next-Generation Sequencing With a 25-Gene Panel Nadine Tung, MD 1,2 ; Chiara Battelli, MD 1 ; Brian Allen,

Hereditary Breast Cancer Testing. clinician guide

Hereditary Breast Cancer Testing clinician guide Ambry s test offerings are designed to provide flexible, comprehensive options tailored to your patients personal and family histories. New Solutions for

BRCA and Other Genetic Abnormalities

Genes and Cancer BRCA and Other Genetic Abnormalities Anne Heun, MS, CGC Certified Genetic Counselor John Stoddard Cancer Center All cancer is GENETIC Tumor suppressor gene: a.k.a. anti-oncogene Important

Breast and Ovarian Cancer

Breast and Ovarian Cancer Hereditary Breast and Ovarian Cancer A Guide for Clinicians KNOWING WHAT TO LOOK FOR KNOWING WHERE TO LOOK AND KNOWING WHAT IT MEANS Hereditary Breast and Ovarian Cancer Panel

Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics

EPAAC WP8 Research Forum - 2 July, Sofitel Hotel Europe, Brussels Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics JY Blay, Past President EORTC

Molecular Human Genetics. Cancer, Tumor suppressor genes, Oncogenes

Youtube ARCC http://www.youtube.com/watch?v=3pobqrfz0no It's Our Time - American Association for Cancer Research (AACR) Molecular Human Genetics Cancer, Tumor suppressor genes, Oncogenes Hum 2014/15 1

6/10/2015. Hereditary Predisposition for Breast Cancer: Looking at BRCA1/BRCA2 Testing & Beyond. Hereditary Cancers. BRCA1 and BRCA2 Review

Hereditary Predisposition for Breast Cancer: Looking at BRCA1/BRCA2 Testing & Beyond Arturo Anguiano MD, FACMG International Medical Director, Medical Affairs Vice Chairman, Genetics; Medical Director,

Evalua&ng tumor exome sequencing in the oncology clinic:

Evalua&ng tumor exome sequencing in the oncology clinic: Lessons from the BASIC3 study GBM Cancer Risk? A Clinical Sequencing Exploratory Research (CSER) project Supported by NHGRI/NCI 1U01HG006485 ISMB2014

Colon Cancer Syndromes. Robin B. Mendelsohn MD Memorial Sloan Kettering Cancer Center Department of Medicine Gastroenterology and Nutrition Service

Colon Cancer Syndromes Robin B. Mendelsohn MD Memorial Sloan Kettering Cancer Center Department of Medicine Gastroenterology and Nutrition Service Background: Etiology of Colorectal Cancer (CRC) Sporadic:

Common Cancers & Hereditary Syndromes

Common Cancers & Hereditary Syndromes Elizabeth Hoodfar, MS, LCGC Regional Cancer Genetics Coordinator Kaiser Permanente Northern California Detect clinical characteristics of hereditary cancer syndromes.

Submitted 12 September 2014; accepted 12 September 2014; advance online publication 13 November 2014. doi:10.1038/gim.2014.147. Genetics in medicine

American College of Medical Genetics and Genomics ACMG Practice Guidelines A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors:

Genomic instability in cancers and cancer predispositions. Popova Tatiana Inserm U830 Institut Curie

Genomic instability in cancers and cancer predispositions Popova Tatiana Inserm U830 Institut Curie Time-scale in a tumor genome discovery Bovery HYP Cancer genome Knudson 2 hit HYP Tumor DNA has transforming

Progress and Prospects in Ovarian Cancer Screening and Prevention

Progress and Prospects in Ovarian Cancer Screening and Prevention Rebecca Stone, MD MS Assistant Professor Kelly Gynecologic Oncology Service The Johns Hopkins Hospital 1 No Disclosures 4/12/2016 2 Ovarian

Cardio Gene panel experience. Jan Jongbloed Laboratory Specialist Clinical Genetics Genome Diagnostics Department of Genetics UMCG Groningen

Cardio Gene panel experience Jan Jongbloed Laboratory Specialist Clinical Genetics Genome Diagnostics UMCG Groningen CardioGenetics: Rowida Almomani Ludolf Boven Anne Herkert Yvonne Hoedemaekers Irene

WHITE PAPER SEPT 2015

WHITE PAPER SEPT 2015 LIQUID BIOPSY FOR THE DETECTION AND MONITORING OF CANCER: ANALYSIS OF 96 HOTSPOT MUTATIONS VIA PLASMA DERIVED CIRCULATING TUMOR DNA PATHWAY GENOMICS CANCER AND SOMATIC MUTATIONS The

Introducing Dorevitch s Genomic Diagnostics

Genetic Testing Introducing Dorevitch s Genomic Diagnostics As one of Australia s longest running and nationally coordinated DNA testing organisations, Dorevitch s Genomic Diagnostics perform specialised

Molecular Pathology/Molecular Diagnostics/Genetic Testing

Policy Number GEN01252012RP Approved By UnitedHealthcare Medicare Reimbursement Policy Committee Current Approval Date 01/28/2015 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is applicable

Examples of The Cancer Genome Atlas (TCGA) Analyses in GenePool

Examples of The Cancer Genome Atlas (TCGA) Analyses in 1. RNA-Seq 2. mirna-seq 3. Protein Expression 4. Somatic Mutations 5. Copy Number 6. DNA Methylation RNA-Seq All primary tumor samples (1,097 of 1,218)

July 14, 2014. Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244

ASCP s Statements before the Centers for Medicare and Medicaid Services Regarding Recommendations for Crosswalking/Gapfilling New CPT s for the CLFS for CY 2015 and the Revaluation of the Clinical Laboratory

Name of Policy: Genetic Testing for Inherited Cancer Predisposition and/or Pharmacogenetics related to Cancer Treatment

Name of Policy: Genetic Testing for Inherited Cancer Predisposition and/or Pharmacogenetics related to Cancer Treatment Policy #: 133 Latest Review Date: April 2015 Category: Laboratory Policy Grade: D

The Role of Next Generation Sequencing in Solid Tumor Mutation Testing

The Role of Next Generation Sequencing in Solid Tumor Mutation Testing Allie H. Grossmann MD PhD Department of Pathology, University of Utah Division of Anatomic Pathology & Oncology, ARUP Laboratories

Next Generation Sequencing in Early-Phase Clinical Trials in Cancer Filip Janku

11 th International Congress on Targeted Anticancer Therapies Paris March 4-6, 2013 Next Generation Sequencing in Early-Phase Clinical Trials in Cancer Filip Janku Investigational Cancer Therapeutics (Phase

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America

Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions

ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes

PRACTICE GUIDELINES nature publishing group 223 CME ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes Sapna Sy nga l, MD, M PH, FAC G 1, 2, 3, R and

Towards new classifications and individualised treatment for cancer patients

Towards new classifications and individualised treatment for cancer patients Professor Thomas TURSZ General Director Institut Gustave Roussy Villejuif Paris - France Workshop Chemores Milano January 21

Metastatic Hereditary Breast Cancer: What s New? Melinda Telli, M.D. Assistant Professor of Medicine Stanford University School of Medicine

Metastatic Hereditary Breast Cancer: What s New? Melinda Telli, M.D. Assistant Professor of Medicine Stanford University School of Medicine Outline Treatment principles in metastatic breast cancer Update

Clinical Use of Molecular Diagnos@cs in the Treatment of Lung Cancer

Clinical Use of Molecular Diagnos@cs in the Treatment of Lung Cancer Tianhong Tina Li, MD, PhD (thli@ucdavis.edu) Associate Professor of Clinical Medicine, School of Medicine Disclosures Grants/Research

CANCER RESEARCH UK STRATIFIED MEDICINE PROGRAMME IAN WALKER PHD, MBA HEAD OF STRATIFIED MEDICINE

CANCER RESEARCH UK STRATIFIED MEDICINE PROGRAMME IAN WALKER PHD, MBA HEAD OF STRATIFIED MEDICINE Agenda Introduction to Cancer Research UK CRUK Stratified Medicine Programme Key Challenges and Lessons

Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer

/, Vol. 7, No. 7 Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer Po-Han Lin 1,2, Wen-Hung Kuo 3, Ai-Chu Huang 2, Yen-Shen Lu 4, Ching-Hung Lin 4, Sung-Hsin

Molecular pathology of thyroid cancers

Molecular pathology of thyroid cancers Peter Lakatos 1st Department of Medicine Semmelweis University Thyroid nodules 4-7% of population with palpable nodules More frequent in women Incidence increasing

Disclosures. Personalized Meds from the molecular onco-pathology s perspective

1 FIGON DMD Symposium From Protocol towards Personalized Tailored Therapy Ede, October 6th 2015 Personalized Meds from the molecular onco-pathology s perspective Diagnostic in Pathology in 2015-2020 Molecular

Immunophenotyping of hereditary breast cancer

Immunophenotyping of hereditary breast cancer Petra van der Groep Cover design: P. van der Groep Lay-out: Gildeprint Drukkerijen - Enschede, The Netherlands Printed by: Gildeprint Drukkerijen - Enschede,

Application of Molecular Diagnosis: Present and Future

Application of Molecular Diagnosis: Present and Future Dong Jun Lim, MD., PhD. Associate Professor Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary s Hospital,

The Future of Clinical Chemistry and Laboratory Medicine, The Diagnostics Industry View

The Future of Clinical Chemistry and Laboratory Medicine, The Diagnostics Industry View Peng Yin, M.D., Ph.D., Director, Global Scientific Affairs Abbott Diagnostic Division (ADD) Agenda Lack of perceived

Name of Policy: Genetic Testing for Inherited Cancer Predisposition and/or Pharmacogenetics related to Cancer Treatment

Name of Policy: Genetic Testing for Inherited Cancer Predisposition and/or Pharmacogenetics related to Cancer Treatment Policy #: 133 Latest Review Date: April 2015 Category: Laboratory Policy Grade: D

Epithelial Ovarian Cancer

Epithelial Ovarian Cancer Fred Ueland, MD University of Kentucky Gynecologic Oncology Risk Factors Incessant ovulation Early menarche, late menopause, low parity Family history Acquired genetic mutations

Stato dell arte e prospettive delle terapie a bersaglio molecolare nel carcinoma polmonare

Stato dell arte e prospettive delle terapie a bersaglio molecolare nel carcinoma polmonare Giorgio V. Scagliotti Università di Torino Dipartimento di scienze cliniche & biologiche giorgio.scagliotti@unito.it

Een behandeling op maat voor iedere patient: wat betekent dat in de praktijk? Emile Voest

Een behandeling op maat voor iedere patient: wat betekent dat in de praktijk? Emile Voest Need for personalised cancer treatment Scenario: patient with metastasized colorectal cancer Doctor suggests treatment

Risk stratification for colorectal cancer especially: the difference between sporadic disease and polyposis syndromes. Dr. med. Henrik Csaba Horváth

Risk stratification for colorectal cancer especially: the difference between sporadic disease and polyposis syndromes Dr. med. Henrik Csaba Horváth Why is risk stratification for colorectal cancer (CRC)

Genomic Clinical Trials: NCI Initiatives

Genomic Clinical Trials: NCI Initiatives James H. Doroshow, M.D. Deputy Director for Clinical and Translational Research National Cancer Institute National Cancer Advisory Board Washington, DC December

Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry

The American Journal of Surgery (2013) 205, 608-612 North Pacific Surgical Association Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer

Molecular Stratification of Cancer in the

Molecular Stratification of Cancer in the Clinical Setting David Gonzalez de Castro Molecular Diagnostics NHS FT and The Institute of Cancer Research, London, UK 1 2 The complexity of human cancer genomes

Genetics of Pancreatic Cancer

Genetics of Pancreatic Cancer Gloria M. Petersen, Ph.D. Mayo Clinic Rochester, Minnesota Pancreatic Cancer Action Network Bloomington, MN Topics Is family history a risk factor for pancreatic cancer? Why

European Biotechnology. News. II Genomic Therapies and & Diagnostics SPECIAL. Science & Industry. April 2013

April 2013 European Biotechnology Science & Industry News II Genomic Therapies and & Diagnostics SPECIAL European Biotechnology Network Join the European Biotechnology Network! The European Biotechnology

Can molecular targeted therapies win the war against cancer?

Can molecular targeted therapies win the war against cancer? DR. PETÁK ISTVÁN PHD KPS MOLEKULÁRIS DIAGNOSZTIKAI KÖZPONT MTA-SE PATHOBIOKÉMIAI MUNKACSOPORT Anti- GEFITINIB An - M+ KRAS Schwab Richárd, Peták

Number 12.04.115 Effective Date December 8, 2015 Revision Date(s) 12/08/15; 06/09/15; 02/10/15; 10/13/14; 05/12/14 Replaces 2.04.

MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Expanded Molecular Panel Testing of Cancers to Identify Targeted

UW Carbone Cancer Center Precision Medicine Molecular Tumor Board V3. 12.18.15 Page 1

The UW Carbone Cancer Center Precision Medicine Molecular Tumor Board In partnership with the UW Collaborative Genomics Core, the UW Carbone Cancer Center (UWCCC) has developed a Precision Medicine Molecular

Essais de médicine personnalisée en cancérologie. Jean-Charles SORIA

Essais de médicine personnalisée en cancérologie Jean-Charles SORIA Cured Cancer patients 2.8 M / year in the EU Local failure Not cured Distant failure Cured Cancer patients 2.8 M / year in the EU Not

Applications of comprehensive clinical genomic analysis in solid tumors: obstacles and opportunities

Applications of comprehensive clinical genomic analysis in solid tumors: obstacles and opportunities Vincent A. Miller, M.D. Foundation Medicine, Inc. AACR Annual Meeting 2012 Current Concepts session

Pancreatic Cancer. Hereditary Pancreatic Cancer A Guide for Clinicians KNOWING WHAT TO LOOK FOR KNOWING WHERE TO LOOK AND KNOWING WHAT IT MEANS

Pancreatic Cancer Hereditary Pancreatic Cancer A Guide for Clinicians KNOWING WHAT TO LOOK FOR KNOWING WHERE TO LOOK AND KNOWING WHAT IT MEANS Hereditary Pancreatic Cancer Panel Advances in molecular genetics

National Medical Policy

National Medical Policy Subject: Policy Number: Genetic Testing for BRCA1 and BRCA2 NMP136 Effective Date*: April 2004 Updated: September 2015 This National Medical Policy is subject to the terms in the

User Guide Thank you for purchasing the DX90 http://www.ibasso.com

Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing

Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing These Are Hopeful Times for Lung Cancer Survivors When people first learn they have cancer, they are often afraid. But

Riesgo genético y familiar. Javier Benitez Centro Nacional Investigaciones Oncológicas Madrid

Riesgo genético y familiar Javier Benitez Centro Nacional Investigaciones Oncológicas Madrid Cancer: An example of complex disease 80-85% of cancers Polygenic model (combination of X genes) Low penetrance

Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers

RESEARCH ARTICLE Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers Nicky D Haene 1, Marie Le Mercier 1, Nancy De Nève 1, Oriane Blanchard 1, Mélanie Delaunoy 2, Hakim

Molecular Diagnosis of Gastrointestinal Tumors

Molecular Diagnosis of Gastrointestinal Tumors Zoltan Szentirmay National Institute of Oncology Center of Surgical and Molecular Tumor Pathology EEA and Norwegian Financial Mechanisms in Hungary, Development